Vânia Mari Salvi Andrzejevski

Vânia Mari Salvi Andrzejevski

Auto-generated profile, based on publicly available information

Vânia Mari Salvi Andrzejevski

Complexo Hospital de Clínicas from the Federal University of Paraná, Curitiba-Paraná, Brazil

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2016 in Pharmacy Practice
Verified
Journal Article
Open access
PDF file
TGThamires B. Galli
Thamires B. Galli
WRWálleri C. Reis
Wálleri C. Reis
VAVânia M. Andrzejevski
Vânia M. Andrzejevski
Potentially inappropriate prescribing and the risk of adverse drug reactions in critically ill older adults

6 March 2016 in Pharmacy Practice
Verified
Journal Article
Open access
PDF file
AMAntonio Eduardo Matoso Mendes
Antonio Eduardo Matoso Mendes
NLNatália F. Lombardi
Natália F. Lombardi
VAVânia S. Andrzejevski
Vânia S. Andrzejevski
GFGibran Frandoloso
Gibran Frandoloso
CCCassyano J. Correr
Cassyano J. Correr
MCMauricio Carvalho
Mauricio Carvalho
Medication reconciliation at patient admission: a randomized controlled trial

5 July 2021 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
APAmanda V Pirolli
Amanda V Pirolli
TBTatiana Brusamarello
Tatiana Brusamarello
SEStella S Everton
Stella S Everton
VAVânia M S Andrzejevski
Vânia M S Andrzejevski
Breast cancer is the most prevalent type of cancer among women, affecting about 2.1 million worldwide and is responsible for the highest number of cancer-related deaths among women. Approximately 80% of breast cancers express on the surface of hormone receptor cells, such as progesterone and estrogen. In these cases, Adjuvant Hormonal Therapy (AHT) is indicated for a period of five to ten years and consists of taking a daily oral pill. The two most used drugs in AHT are tamoxifen and Aromatase Inhibitors. One of the issues most faced by individuals who are subjected to long periods of treatment is the lack of medication adherence and, consequently, therapeutic inefficiency. It is believed that the monitoring by the pharmacist can contribute to the reduction of errors inherent to the medication, making the treatment more effective and improving the patient's quality of life. The present study aimed to know the perception of patients who live with breast cancer and who do AHT in relation to the educational performance of the clinical pharmacist. This is a qualitative, descriptive and exploratory study, carried out from March to October 2020, with 15 women undergoing treatment at the oncology unit of a tertiary-care hospital in south of Brazil. The data were obtained through a semi-structured interview using an instrument composed of two parts, one referring to the characterization of the participants and the other with the guiding question of the research: "How do you perceive the role of the pharmacist in relation to the guidelines for the use of adjuvant hormonal therapy?". The method of theoretical saturation was used to perform the sample closure and the thematic analysis was used to analyze the data. The participants were between 32 and 74 years old, seven were on tamoxifen therapy and eight on anastrozole, ten were on the first year of treatment, two on the second and three on the third year. The themes that emerged were: pharmacist-patient interaction as a safety factor in hormone therapy; role of the pharmacist in the development of strategies for self-management of the patients during hormone therapy; and, challenges for the pharmacist in relation to hormone therapy through continued guidance. It was evident that the pharmacist's educational action encouraged the participants to carry out the treatment in a more confident and assertive manner according to their particularities and beliefs.

19 June 2015 in Pharmacy Practice
Verified
Journal Article
Open access
PDF file
LOLucas Miyake Okumura
Lucas Miyake Okumura
VAValquíria D. Antunes
Valquíria D. Antunes
KAKarina Aguiar
Karina Aguiar
TFTatiane Farias
Tatiane Farias
VAVánia M. Andrzejevski
Vánia M. Andrzejevski
VFVaneuza ARAUJO MOREIRA Funke
Vaneuza ARAUJO MOREIRA Funke
To assess the role of social risk factors on adherence to tyrosine kinase inhibitors (TKI) therapy in chronic myeloid leukemia (CML) patients. This is a retrospective study and eligible patients were adults with CML on TKI treatment. Cases of no adherence to treatment were confirmed during pharmacists’ consultation (patient-reported adherence). Baseline characteristics between groups were compared between cases and controls groups. Risk factors identified in bivariate analysis (p<0.2) were included in multivariate model. A qualitative investigation assessed whether such predictors of non-adherence had causal relationship. Of 151 patients with CML consulted by pharmacists, 21% had adherence problems. Despite patients with secondary school (p=0.03), most of investigated social risk factors did not differ between groups. However, by using a qualitative approach, patients’ level of education could not explain low adherence rates behavior. Social determinants of health, herein investigated, were unlikely to predict adherence to treatment. Regression techniques may lead to untrue statements, so future researches should consider investigating the causes, not only the statistical estimates.

22 February 2021 in Revista Brasileira de Cancerologia
Verified
Journal Article
Open access
PDF file
VAVânia Mari Salvi Andrzejevski
Vânia Mari Salvi Andrzejevski
SPSérgio Lunardon Padilha
Sérgio Lunardon Padilha
JFJorge Vinícius Cestari Felix
Jorge Vinícius Cestari Felix
FNFrancisco Diego Negrão Lopes Neto
Francisco Diego Negrão Lopes Neto
JNJosé Zanis Neto
José Zanis Neto
Introduction: Adherence to oral antineoplastics (OA) is an important indicator of therapeutic response related to personal, social, and structural factors. Objective: To determine rates of adherence to OA, investigating possible risk factors for nonadherence and to assess patient beliefs about medication, identifying opportunities for pharmaceutical intervention. Method: An analytical study was conducted with cancer patients using OA in 2015. Adherence to Refills and Medication Scale (ARMS) and Beliefs about Medicines Questionnaire (BMQ) were applied to assess adherence and beliefs about medication and treatment. Mann-Whitney, Chi-square, and Fisher’s Exact tests were used for data analysis. Results: A total of 222 patients were interviewed, with a 92.8% adherence rate according to ARMS and 84.7% according to BMQ, in which the necessity-beliefs exceeded the concerns with the treatment and use of OA. Family income, treatment interruption, number and causes of interruptions, depression, and medication possession ratio were the risk factors identified. Comparison of BMQ domains showed that, in the adherent group, patient beliefs in the necessity of the medication exceeded their concerns about it. Conclusion: Understanding the patient’s beliefs is a decisive factor in comprehending the risks related to nonadherence as well as in defining strategies to deal with it.